Last edition
News about Biotechnology
Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Worth Over USD 1 Billion
Eli Lilly & Company is in advanced discussions to acquire Ventyx Biosciences in a deal valued at more than USD 1 billion, according to reports citing people familiar with the matter. The acquisition talks have attracted strong investor interest, with Ventyx shares rising sharply following the news.
Biotechnology | 07/01/2026 | By Darshana | 207
WuXi Biologics, a global contract research, development and manufacturing organisation (CRDMO), has achieved ISO 20400 Sustainable Procurement certification, a globally recognised standard that embeds sustainability principles into procurement practices and promotes transparency, accountability and responsible supply chain management.
Biotechnology | 06/01/2026 | By Darshana | 167
Pandorum Partners with Nucelion Therapeutics to Manufacture Exosome-Based Ocular Therapy for APAC
Pandorum Technologies, a clinical-stage regenerative medicine company, has entered into a strategic manufacturing collaboration with Nucelion Therapeutics, the contract research, development and manufacturing organisation (CRDMO) arm of Bharat Biotech, to support the production of its exosome-based ocular disease therapy for the Asia-Pacific (APAC).
Biotechnology | 06/01/2026 | By Darshana | 225
BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV Structure
BioAtla, Inc., a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapies for solid tumours, has entered into a special purpose vehicle (SPV) transaction with GATC Health Corp. to advance its lead asset, ozuriftamab vedotin (Oz-V), into a phase 3 clinical trial for second-line and later OPSCC.
Biotechnology | 04/01/2026 | By Darshana | 222
Mabwell Advances ADC Manufacturing Pipeline With NMPA-Backed Combination Trial Approval
Mabwell, an innovation-driven biopharmaceutical company with fully integrated capabilities spanning research and development, manufacturing, and commercialisation, announced that China’s National Medical Products Administration (NMPA) has approved the initiation of clinical trials for its independently developed B7-H3–targeting antibody–drug conjugate.
Biotechnology | 02/01/2026 | By Darshana | 231
Azenta Signs Definitive Agreement to Sell B Medical Systems to Thelema for USD 63 Million
Azenta, Inc., a leading provider of life sciences solutions worldwide, announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to Thelema S.À R.L., for a purchase price of USD 63 million. The transaction is expected to close on or before March 31, 2026.
Biotechnology | 30/12/2025 | By Darshana | 179
S&T Minister Dr Jitendra Singh inaugurates Biotechnology Research and Innovation Council (BRIC)
Union Minister of State (Independent Charge) for Science and Technology (S&T) Dr Jitendra Singh formally inaugurated the Biotechnology Research and Innovation Council (BRIC) Secretariat, on 29 December, by unveiling the inaugural curtain, marking the official opening of a new milestone in India’s biotechnology journey.
Biotechnology | 30/12/2025 | By Darshana | 117
GENESIS Pharma Secures Exclusive Rights to Commercialise Donidalorsen Across 14 CEE Markets
GENESIS Pharma, a regional biopharma company specialising in the commercialisation of innovative medicines in Central and Eastern Europe (CEE), has entered into an exclusive agreement with Otsuka Pharmaceutical Europe Ltd., the European arm of Otsuka Pharmaceutical Co., Ltd., for the distribution and commercialisation of donidalorsen.
Biotechnology | 16/12/2025 | By Darshana | 255
Vektor Medical Secures FDA Clearance for Next-Generation vMap Arrhythmia Mapping Technology
Vektor Medical, a San Diego–headquartered medical technology company focused on advancing arrhythmia diagnosis and treatment, has received US Food and Drug Administration 510(k) clearance for its next-generation vMap technology.
Biotechnology | 14/12/2025 | By Darshana | 349
Sentynl Appoints myTomorrows as Global Provider to Expand Managed Access Program
Sentynl Therapeutics, a biopharmaceutical company based in the USA and wholly owned by Zydus Lifesciences, has appointed myTomorrows as the global provider for its Managed Access Program (MAP).
Biotechnology | 11/12/2025 | By Darshana | 138
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy